In evolocumab studies, treatment-emergent antibodies were reported in just one patient [28]. In familial hypercholesterolemia patients, the SPIRE (Studies of PCSK9 Inhibition and the Reduction of Vascular Events) trial demonstrated cardiovascular risk reduction with bococizumab [29]. Here, PCSK9 is linked to familial hypercholesterolemia.